<DOC>
	<DOCNO>NCT00146627</DOCNO>
	<brief_summary>The purpose study compare therapeutic combination I.V . eflornithine + oral nifurtimox standard IV eflornithine regimen term therapeutic efficacy clinical safety , patient suffer Trypanosoma brucei gambiense ( Tbg ) human African trypanosomiasis ( HAT ) meningoencephalitic phase .</brief_summary>
	<brief_title>Efficacy - Safety Eflornithine-Nifurtimox Combination Versus Eflornithine Treat Human African Trypanosomiasis</brief_title>
	<detailed_description>Melarsoprol commonly use product treatment patient suffer human African trypanosomiasis ( HAT ) meningoencephalitic ( second , late ) phase . This treatment frequently complicate fatal reactive encephalopathy , time resistance begin appear various country . Eflornithine effective well tolerate , difficult use . Nifurtimox , register several South American country treatment Chagas ' disease use label since 1970 's series case meningo-encephalitic HAT , present potential alternative treatment late-stage HAT . The limited number compound available , lack prospect development new product emergence resistance argument use therapeutic combination . Ideally , drug combination allow reduction dosage drug use way , particular case toxic drug use second stage HAT , toxicity combination exceed either monotherapy . Of three drug combination nowadays possible : melarsoprol-nifurtimox , melarsoprol-eflornithine eflornithine-nifurtimox , last one ( two different dose regimen ) show least treatment-associated toxicity mortality 69 patient treat one previous clinical trial date . Good tolerability also observe case series 31 patient . The efficacy data date suggest efficacy comparable eflornithine melarsoprol ( area without high melarsoprol failure rate ) .</detailed_description>
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<mesh_term>Nifurtimox</mesh_term>
	<criteria>confirm secondstage T.b . gambiense infection : presence parasite blood , lymph node fluid CSF &gt; 20 white blood cells/µL CSF . In presence blood CSF , lumbar puncture must do patient include study ( see 10.9.1 ) . age 15 year old . resident __________ ( site define boundary maximum distance ) write informed consent patient legally acceptable representative patient minor ( &lt; 18 year gender Uganda Angola , &lt; 18 year males &lt; 16 year females Democratic Republic Congo ) unable communicate . pregnant woman ( systematic test woman childbearing potential ) treat latestage HAT last 36 month . Patients previously treat firststage ( pentamidine ) include . unlikely access treatment centre accessible place residence 18 month treatment unable take oral medication suffer condition second stage HAT seriously limit chance survival 18 month time Severe anemia ( Hb &lt; 5g/dl ) Severe underlie disease upon admission ( e.g . Active tuberculosis and/or treat TB ; Bacterial cryptococcal meningitis ; Stages 3 4 HIV/AIDS accord WHO clinical definition ) ( WHO , 1986 ) . Severe renal failure base clinical examination combine biochemistry available : creatinine clearance &lt; 20mL/min Severe hepatic failure base clinical examination combine biochemistry available : total bilirubin &gt; 50 µmol/L , ALAT/GPT &gt; 70 UI/L , unless laboratory value determine investigator likely due condition hepatic failure .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Human African Trypanosomiasis</keyword>
	<keyword>Combination</keyword>
	<keyword>Trypanosoma brucei gambiense Human African Trypanosomiasis</keyword>
</DOC>